FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including isolated polynucleotide encoding polypeptide containing a heavy chain variable domain (VH) of an antibody, which binds to a sialylated Lewisa antigen (options), isolated polypeptide containing an antigen-binding site of an antibody, which binds to a sialylated Lewisa antigen, a pharmaceutical composition for the treatment of a disease, where a disease is malignant neoplasm or tumor neoplasm with cells expressing a sialylated Lewisa antigen, and a method for the treatment or prevention of a disease, including administration of a pharmaceutical composition.
EFFECT: invention expands the arsenal of remedies specifically binding to a sialylated Lewisa antigen.
15 cl, 25 dwg, 12 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS | 2014 |
|
RU2699289C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
| ANTIBODIES THAT BIND TO CANCER CELLS AND PROVIDE TARGETED TRANSFER OF RADIONUCLIDES TO SAID CELLS | 2020 |
|
RU2833191C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
| BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | 2020 |
|
RU2832083C2 |
